BIOCRYST PHARMACEUTICALS INC (BCRX) earnings date
Feb 22, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | before open | 35 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | before open | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | before open | 36 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | before open | 34 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | before open | 35 | 8-K |
| Q1 FY2025 | Mon, May 5, 2025 | before open | 35 | 8-K |
| Q4 FY2024 | Mon, Feb 24, 2025 | before open | 55 | 8-K |
What they guided beta
| Q3 FY2026 | "EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Third Quarter 2026 Financial Results — Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — — Improved Non-GAAP operating expense guidance to $415 to $425 million — — Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older" exhibit |
| Q3 FY2026 | "The program remains on track to report top-line results at six- and twelve-month endpoints in Q3 2027." exhibit |
| Q3 FY2026 | "The company has enrolled Part 4 of this trial and expects to report initial data in patients with NS by the end of 2026." exhibit |
| Q3 FY2026 | "Financial Outlook for 2026 The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million and increased its full year 2026 total revenue outlook, including revenue from RAPIVAB ® (peramivir injection) and the licensing of navenibart European rights, to $715 million to $730 million." exhibit |
| Q3 FY2026 | "The company improved its outlook for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to $415 million to $425 million." exhibit |
| Q2 FY2026 | "EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — — Began shipping ORLADEYO oral pellets to pediatric patients on August 3 — — Completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart — R" exhibit |
| Q2 FY2026 | "The program remains on track to report top-line results from both doses in Q3 2027." exhibit |
| Q2 FY2026 | "The company is dosing in Part 4 of this trial, which will enroll up to 12 patients for three months, and expects to report data from this part by the end of 2026." exhibit |
| Q2 FY2026 | "Financial Outlook for 2026 The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million." exhibit |
| Q2 FY2026 | "The company raised the full year 2026 total revenue outlook, including RAPIVAB ® (peramivir injection) and revenue from the licensing of navenibart European rights, to $690 million to $715 million." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/BCRX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/BCRX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/BCRX/"><img src="https://veritasdata.dev/embed/BCRX.svg" alt="BCRX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/BCRX/)
Script
<script async src="https://veritasdata.dev/embed/BCRX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/BCRX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.